KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Cash & Equivalents (2016 - 2025)

Astrazeneca (AZN) has 3 years of Cash & Equivalents data on record, last reported at $5.7 billion in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 3.86% year-over-year to $5.7 billion; the TTM value through Dec 2025 reached $5.7 billion, up 3.86%, while the annual FY2025 figure was $5.7 billion, 3.86% up from the prior year.
  • Cash & Equivalents reached $5.7 billion in Q4 2025 per AZN's latest filing, up from $5.5 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $5.7 billion in Q4 2025 and bottomed at $1.3 billion in Q4 2023.
  • Average Cash & Equivalents over 3 years is $4.2 billion, with a median of $5.5 billion recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: soared 314.19% in 2024, then increased 3.86% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $1.3 billion in 2023, then skyrocketed by 314.19% to $5.5 billion in 2024, then increased by 3.86% to $5.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $5.7 billion in Q4 2025, $5.5 billion in Q4 2024, and $1.3 billion in Q4 2023.